The improved transgene delivery and efficacy of an Ad.5/3 recombinant virus expressing mda-7/IL-24, has been demonstrated in prostate cancer, glioma, colorectal, and renal cancer [58,92,93,94]. This evidence concerns the gene IL24 and renal carcinoma.